VRCA
Verrica Pharmaceuticals Inc.
Nasdaq: VRCA · West Chester, PA · Healthcare
$6.32-0.06 (-0.94%)Closed
Market Cap$108.6M
Cash$30.1Mmost recent
Runway7 mo$12.7M Q burn
P/E (TTM)—EPS $-1.68
52-Wk Range$3.28 – $9.10
Avg Volume169.8K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$6.32-90.7%
Pipeline

Drug candidates sponsored by Verrica Pharmaceuticals · ClinicalTrials.gov

8 drugs · 8 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3Unnamed
Molluscum Contagiosum
Completed
2018-09-26past
1
Phase 3Unnamed
Molluscum Contagiosum
Completed
2018-11-26past
1
Phase 3Unnamed
Common Warts+3 more
Recruiting
2027-06
1
Phase 3Unnamed
Common Warts (Verruca Vulgaris)+3 more
Not yet recruiting
2028-04-30
1
Phase 2Unnamed
Molluscum Contagiosum
Completed
2018-06-25past
1
Phase 2Unnamed
Common Wart+11 more
Completed
2019-05-16past
1
Phase 2Unnamed
Condylomata Acuminata+7 more
Completed
2020-05-21past
1
Phase 2Part 1: VP-315 3 Day Dosing/Week
Basal Cell Carcinoma+4 more
Completed
2024-04-15past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for VRCA. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.